Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – July 25, 2024 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first half of 2024. Business highlights ...
Idorsia will publish its Half Year 2024 Financial Reporting on Thursday July 25, 2024, at 07:00 CEST. An investor conference call and webcast will be held to discuss the results on the same day. ...
EU regulator clears Idorsia’s Jeraygo to resistant hypertension
Idorsia Ltd (SIX: IDIA) announced today that the European Commission (EC) has approved JERAYGO™ (aprocitentan) for the treatment of resistant hypertension in adult patients in combination with at least three antihypertensive medicinal products.1 The recommended dose is 12.5 mg orally once daily. The dose can be increased to 25 mg once daily for patients tolerating the 12.5 mg dose and in need of tighter blood pressure (BP) control.1
Allschwil, Switzerland – June 28, 2024 Idorsia Ltd (SIX: IDIA) today announced that it has received the written decision from the higher cantonal composition authority (obere kantonale...
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – June 25, 2024 Idorsia Ltd (SIX: IDIA) today announced that the hearing by the higher cantonal composition authority (obere...
All Board proposals approved by the shareholders Allschwil, Switzerland – June 13, 2024At today’s Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Basel, Switzerland, shareholders...
Allschwil, Switzerland – June 3, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data with daridorexant, Idorsia’s dual orexin receptor antagonist for the treatment of adults with insomnia,...
Allschwil, Switzerland “ May 31, 2024 Idorsia Ltd (SIX: IDIA) today announced that data from the Phase 3 study of aprocitentan, Idorsia's endothelin receptor antagonist, will be presented by Prof....
Jean-Paul Clozel is ready to pass the torch at his Actelion follow-up Idorsia, but he doesn’t want to walk away from the company altogether